Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

NCT ID: NCT03634787

Last Updated: 2018-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

280 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-20

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis. In addition to test the potential treatment target of acute pancreatitis.

All patients who present with clinical symptoms of acute pancreatitis are evaluated for the enrollment of the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients with acute pancreatitis are evaluated according to modified Atlanta classification acute pancreatitis severity scores.

Blood serum, urine and DNA samples are collected from all patients presented on admission, after 24 hours, 48 hours, 72 hours.

CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital admission. If necrosis is not present follow-up is stopped.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute pancreatitis

First time acute pancreatitis. No later than 2 days since the clinical symptoms started.

CT Scan Day 5-7

Intervention Type DIAGNOSTIC_TEST

Computed Tomography on Day 5-7 according to a clinical protocol.

Healthy

No major systemic illness

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CT Scan Day 5-7

Computed Tomography on Day 5-7 according to a clinical protocol.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* no prior diagnosis of acute pancreatitis
* admission to the hospital within 2 days since the clinical symptoms
* confirmed diagnosis of acute pancreatitis

Exclusion Criteria

* chronic pancreatitis
* pancreatic cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vilnius University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aiste Gulla

Senior surgery resident

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vilnius University Hospital "Santaros Klinikos

Vilnius, , Lithuania

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lithuania

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kestutis Strupas, Prof. MD/PhD

Role: CONTACT

+37052365000

Aiste Gulla, MD

Role: CONTACT

+37052365000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kestutis Strupas, Prof.MD/PhD

Role: primary

+3705236500

Aiste Gulla, MD

Role: backup

+37052365000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

158200-17-941-455

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PERT in Acute Necrotizing Pancreatitis
NCT07211568 NOT_YET_RECRUITING PHASE3
Imaging Biomarkers of Pancreatic Function and Disease
NCT05659147 ENROLLING_BY_INVITATION PHASE4